Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

28.02
-0.0550-0.20%
Volume:3.62M
Turnover:101.32M
Market Cap:159.29B
PE:36.87
High:28.16
Open:28.11
Low:27.82
Close:28.07
52wk High:28.75
52wk Low:23.58
Shares:5.69B
Float Shares:5.64B
Volume Ratio:0.93
T/O Rate:0.06%
Dividend:1.72
Dividend Rate:6.14%
EPS(TTM):0.7599
EPS(LYR):1.36
ROE:5.01%
ROA:5.78%
PB:1.87
PE(LYR):20.53

Loading ...

Pfizer (PFE) Valuation Check After Recent Share Price Pressure And Rebuilding Momentum

Simply Wall St.
·
Jun 04

Pfizer’s Bevacizumab Biosimilar Safety Study in Japan Reaches Completion: What Investors Should Watch

TIPRANKS
·
Jun 04

Pfizer’s ODEN Study Update: Real-World Data on Tofacitinib in Ulcerative Colitis

TIPRANKS
·
Jun 04

AlphaSense nearly doubles valuation to $7.5 billion in new funding round

Reuters
·
Jun 03

Bernstein Keeps Their Hold Rating on Pfizer (PFE)

TIPRANKS
·
Jun 02

Pfizer Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Jun 02

Moderately bullish activity in Pfizer with shares down 2.08%

TIPRANKS
·
Jun 02

Pfizer CEO Bourla to speak at Goldman Sachs global healthcare conference webcast

Reuters
·
Jun 01

FDA approves FoundationOne CDx, Liquid CDx as TALZENNA-XTANDI companion diagnostics in prostate cancer

Reuters
·
Jun 01

Pfizer's Braftovi Regimen Cuts Risk of Progression, Death in Phase 3 Trial in Colorectal Cancer

MT Newswires Live
·
Jun 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and BioNTech SE (BNTX)

TIPRANKS
·
Jun 01

Analyst Maintains Hold on Pfizer, Keeps Price Target Unchanged at $27 Amid Pipeline Uncertainties

TIPRANKS
·
Jun 01

Pfizer announces results from Cohort 3 on Bratovi with cetuximab, Folfiri

TIPRANKS
·
May 31

Pfizer announces results from Phase 3 Talapro-3 study of Talzenna, Xtandi

TIPRANKS
·
May 31

Pfizer’s Braftovi Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

THOMSON REUTERS
·
May 31

Pfizer Pivots to Obesity and Oncology as Wall Street Waits

TIPRANKS
·
May 30

Pfizer - Talzenna Plus Xtandi Improves Radiographic Progression-Free Survival by Over 50% in Metastatic Prostate Cancer

THOMSON REUTERS
·
May 30

Pfizer’s VESPER-4 Obesity Trial Signals a Serious Push Into the GLP-1 Growth Market

TIPRANKS
·
May 30

Pfizer’s Real-World Lung Cancer Study on Dacomitinib: What Investors Should Know

TIPRANKS
·
May 30

Pfizer: European Commission Authorizes Update to Pediatric Use of Pfizer and BioNTech Covid 19 Vaccine

THOMSON REUTERS
·
May 29